Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Targeting CXCR1/2 Does No… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

Artikel i vetenskaplig tidskrift
Författare P. Maffi
T. Lundgren
G. Tufveson
E. Rafael
J. A. M. Shaw
A. Liew
F. Saudek
P. Witkowski
K. Golab
F. Bertuzzi
Bengt Gustafsson
L. Daffonchio
P. A. Ruffini
L. Piemonti
R. Nano
A. Mercalli
V. Lampasona
P. Magistretti
V. Sordi
S. Antonio
B. Antonioli
M. Galuzzi
M. C. Tosca
L. De Carlis
G. Colussi
O. Korsgren
H. Pollard
Publicerad i Diabetes Care
Volym 43
Nummer/häfte 4
Sidor 710-718
ISSN 0149-5992
Publiceringsår 2020
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi
Sidor 710-718
Språk en
Länkar dx.doi.org/10.2337/dc19-1480
Ämnesord beta-cell function, antiinflammatory strategies, inhibition, induction, immunosuppression, engraftment, survival, regimen, Endocrinology & Metabolism
Ämneskategorier Endokrinologi och diabetes

Sammanfattning

OBJECTIVE Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients. RESEARCH DESIGN AND METHODS A phase 3, multicenter, randomized, double-blind, parallel-assignment study () was conducted in recipients of islet allotransplants randomized (2:1) to reparixin or placebo in addition to immunosuppression. Primary outcome was the area under the curve (AUC) for C-peptide during the mixed-meal tolerance test at day 75 +/- 5 after the first and day 365 +/- 14 after the last transplant. Secondary end points included insulin independence and standard measures of glycemic control. RESULTS The intention-to-treat analysis did not show a significant difference in C-peptide AUC at both day 75 (27 on reparixin vs. 18 on placebo, P = 0.99) and day 365 (24 on reparixin vs. 15 on placebo, P = 0.71). There was no statistically significant difference between treatment groups at any time point for any secondary variable. Analysis of patient subsets showed a trend for a higher percentage of subjects retaining insulin independence for 1 year after a single islet infusion in patients receiving reparixin as compared with patients receiving placebo (26.7% vs. 0%, P = 0.09) when antithymocyte globulin was used as induction immunosuppression. CONCLUSIONS In this first double-blind randomized trial, islet transplantation data obtained with reparixin do not support a role of CXCR1/2 inhibition in preventing islet inflammation-mediated damage.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?